发布求助
文献互助 智能选刊 最新文献

Clinical and Molecular Hepatology最新文献

筛选
英文 中文
Correspondence on Editorial regarding"Macrophage ATG16L1: potential candidate for MASH treatment". 关于 "巨噬细胞 ATG16L1：治疗 NASH 的潜在候选者 "社论的通信。
IF 14 1区 医学
Clinical and Molecular Hepatology Pub Date : 2024-07-08 DOI: 10.3350/cmh.2024.0470
Qi Wang, Qingfa Bu, Haoming Zhou, Ling Lu
{"title":"Correspondence on Editorial regarding\"Macrophage ATG16L1: potential candidate for MASH treatment\".","authors":"Qi Wang, Qingfa Bu, Haoming Zhou, Ling Lu","doi":"10.3350/cmh.2024.0470","DOIUrl":"10.3350/cmh.2024.0470","url":null,"abstract":"","PeriodicalId":10275,"journal":{"name":"Clinical and Molecular Hepatology","volume":null,"pages":null},"PeriodicalIF":14.0,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141554246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of SPP1 in MASLD pathogenesis: Therapeutic insights into ursolic acid's mechanisms of action. SPP1 在 MASLD 发病机制中的作用：熊果酸作用机制的治疗启示。
IF 14 1区 医学
Clinical and Molecular Hepatology Pub Date : 2024-07-08 DOI: 10.3350/cmh.2024.0471
Yiyuan Zheng, Zhekun Xiong, Lina Zhao, Chaoyuan Huang, Qiuhong Yong, Dan Fang, Fengbin Liu, Yong Li
{"title":"The role of SPP1 in MASLD pathogenesis: Therapeutic insights into ursolic acid's mechanisms of action.","authors":"Yiyuan Zheng, Zhekun Xiong, Lina Zhao, Chaoyuan Huang, Qiuhong Yong, Dan Fang, Fengbin Liu, Yong Li","doi":"10.3350/cmh.2024.0471","DOIUrl":"https://doi.org/10.3350/cmh.2024.0471","url":null,"abstract":"","PeriodicalId":10275,"journal":{"name":"Clinical and Molecular Hepatology","volume":null,"pages":null},"PeriodicalIF":14.0,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141554249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nucleos(t)ide Analog Therapy of Chronic Hepatitis B and Extrahepatic Cancer Risk: Is tenofovir better than entecavir? 核苷（t）ide 类似物治疗慢性乙型肝炎与肝外癌症风险：替诺福韦比恩替卡韦更好吗？
IF 14 1区 医学
Clinical and Molecular Hepatology Pub Date : 2024-07-08 DOI: 10.3350/cmh.2024.0519
Yewan Park, Dong Hyun Sinn
{"title":"Nucleos(t)ide Analog Therapy of Chronic Hepatitis B and Extrahepatic Cancer Risk: Is tenofovir better than entecavir?","authors":"Yewan Park, Dong Hyun Sinn","doi":"10.3350/cmh.2024.0519","DOIUrl":"https://doi.org/10.3350/cmh.2024.0519","url":null,"abstract":"","PeriodicalId":10275,"journal":{"name":"Clinical and Molecular Hepatology","volume":null,"pages":null},"PeriodicalIF":14.0,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141554248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dipeptidyl peptidase-4 inhibitors are associated with improved survival of patients with diabetes mellitus and hepatocellular carcinoma receiving immunotherapy. 二肽基肽酶-4 抑制剂与接受免疫疗法的糖尿病和肝细胞癌患者生存率的提高有关。
IF 14 1区 医学
Clinical and Molecular Hepatology Pub Date : 2024-07-04 DOI: 10.3350/cmh.2024.0280
Dorothy Cheuk-Yan Yiu, Huapeng Lin, Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Ken Liu, Terry Cheuk-Fung Yip
{"title":"Dipeptidyl peptidase-4 inhibitors are associated with improved survival of patients with diabetes mellitus and hepatocellular carcinoma receiving immunotherapy.","authors":"Dorothy Cheuk-Yan Yiu, Huapeng Lin, Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Ken Liu, Terry Cheuk-Fung Yip","doi":"10.3350/cmh.2024.0280","DOIUrl":"https://doi.org/10.3350/cmh.2024.0280","url":null,"abstract":"","PeriodicalId":10275,"journal":{"name":"Clinical and Molecular Hepatology","volume":null,"pages":null},"PeriodicalIF":14.0,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141533799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metabolic-associated fatty liver disease is less effective in predicting mortality than non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease. 在预测死亡率方面，代谢相关性脂肪肝不如非酒精性脂肪肝和代谢功能障碍相关性脂肪肝有效。
IF 14 1区 医学
Clinical and Molecular Hepatology Pub Date : 2024-07-04 DOI: 10.3350/cmh.2024.0417
Yixuan Zhu, Yee Hui Yeo, Xiaoyan Ma, Wenjing Ni, Junping Shi, Jie Li
{"title":"Metabolic-associated fatty liver disease is less effective in predicting mortality than non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease.","authors":"Yixuan Zhu, Yee Hui Yeo, Xiaoyan Ma, Wenjing Ni, Junping Shi, Jie Li","doi":"10.3350/cmh.2024.0417","DOIUrl":"https://doi.org/10.3350/cmh.2024.0417","url":null,"abstract":"","PeriodicalId":10275,"journal":{"name":"Clinical and Molecular Hepatology","volume":null,"pages":null},"PeriodicalIF":14.0,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141533826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Class II Transactivator Restricts Viral Replication, Extending its Effect to HBV. 二类反式激活因子限制病毒复制，扩大对 HBV 的影响。
IF 14 1区 医学
Clinical and Molecular Hepatology Pub Date : 2024-07-03 DOI: 10.3350/cmh.2024.0465
Cho-Rong Lee, Sung-Gyoo Park
{"title":"Class II Transactivator Restricts Viral Replication, Extending its Effect to HBV.","authors":"Cho-Rong Lee, Sung-Gyoo Park","doi":"10.3350/cmh.2024.0465","DOIUrl":"https://doi.org/10.3350/cmh.2024.0465","url":null,"abstract":"","PeriodicalId":10275,"journal":{"name":"Clinical and Molecular Hepatology","volume":null,"pages":null},"PeriodicalIF":14.0,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141491125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients. EDP-514 对未经治疗的病毒血症慢性乙型肝炎患者的安全性、药代动力学和抗病毒活性的 1 期试验。
IF 14 1区 医学
Clinical and Molecular Hepatology Pub Date : 2024-07-01 Epub Date: 2024-03-26 DOI: 10.3350/cmh.2023.0535
Man-Fung Yuen, Wan-Long Chuang, Cheng-Yuan Peng, Wen-Juei Jeng, Wei-Wen Su, Ting-Tsung Chang, Chi-Yi Chen, Yao-Chun Hsu, Guy De La Rosa, Alaa Ahmad, Ed Luo, Annie L Conery
{"title":"Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients.","authors":"Man-Fung Yuen, Wan-Long Chuang, Cheng-Yuan Peng, Wen-Juei Jeng, Wei-Wen Su, Ting-Tsung Chang, Chi-Yi Chen, Yao-Chun Hsu, Guy De La Rosa, Alaa Ahmad, Ed Luo, Annie L Conery","doi":"10.3350/cmh.2023.0535","DOIUrl":"10.3350/cmh.2023.0535","url":null,"abstract":"<p><strong>Background/aims: </strong>Oral EDP-514 is a potent core protein inhibitor of hepatitis B virus (HBV) replication, which produced a >4-log viral load reduction in HBV-infected chimeric mice with human liver cells. This study evaluated the safety, pharmacokinetics, and antiviral activity of three doses of EDP-514 in treatment-naive viremic patients with HBeAgpositive or -negative chronic HBV infection.</p><p><strong>Methods: </strong>Patients with HBsAg detectable at screening and at least 6 months previously were eligible. HBeAg-positive and -negative patients had a serum/plasma HBV DNA level ≥20,000 and ≥2,000 IU/mL, respectively. Twenty-five patients were randomized to EDP-514 200 (n=6), 400 (n=6) or 800 mg (n=7) or placebo (n=6) once daily for 28 days.</p><p><strong>Results: </strong>A dose-related increase in EDP-514 exposure (AUClast and Cmax) was observed across doses. At Day 28, mean reductions in HBV DNA were -2.9, -3.3, -3.5 and -0.2 log10 IU/mL with EDP-514 200 mg, 400 mg, 800 mg, and placebo groups, respectively. The corresponding mean change from baseline for HBV RNA levels was -2.9, -2.4, -2.0, and -0.02 log10 U/mL. No virologic failures were observed. No clinically meaningful changes from baseline were observed for HBsAg, HBeAg or HBcrAg. Nine patients reported treatment emergent adverse events of mild or moderate severity with no discontinuations, serious AEs or deaths.</p><p><strong>Conclusion: </strong>In treatment-naïve viremic patients, oral EDP-514 was generally safe and well-tolerated, displayed PK profile supportive of once-daily dosing, and markedly reduced HBV DNA and HBV RNA.</p>","PeriodicalId":10275,"journal":{"name":"Clinical and Molecular Hepatology","volume":null,"pages":null},"PeriodicalIF":14.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11261219/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140287016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A New Korean Nomenclature for Steatotic Liver Disease. 韩国脂肪肝新命名法。
IF 14 1区 医学
Clinical and Molecular Hepatology Pub Date : 2024-07-01 DOI: 10.3350/cmh.2024.0467
Byoung Kuk Jang, Dae Won Jun, Sang Gyune Kim, Seung Up Kim, Won Kim, Sung Won Lee, Ju Hyun Shim, Su Jong Yu
{"title":"A New Korean Nomenclature for Steatotic Liver Disease.","authors":"Byoung Kuk Jang, Dae Won Jun, Sang Gyune Kim, Seung Up Kim, Won Kim, Sung Won Lee, Ju Hyun Shim, Su Jong Yu","doi":"10.3350/cmh.2024.0467","DOIUrl":"https://doi.org/10.3350/cmh.2024.0467","url":null,"abstract":"","PeriodicalId":10275,"journal":{"name":"Clinical and Molecular Hepatology","volume":null,"pages":null},"PeriodicalIF":14.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141466587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Severity of microvascular invasion does matter in hepatocellular carcinoma prognosis. 微血管侵犯的严重程度对肝癌预后有影响。
IF 14 1区 医学
Clinical and Molecular Hepatology Pub Date : 2024-07-01 DOI: 10.3350/cmh.2024.0482
Abdelrahman M Attia, Hasmik Adetyan, Ju Dong Yang
{"title":"Severity of microvascular invasion does matter in hepatocellular carcinoma prognosis.","authors":"Abdelrahman M Attia, Hasmik Adetyan, Ju Dong Yang","doi":"10.3350/cmh.2024.0482","DOIUrl":"https://doi.org/10.3350/cmh.2024.0482","url":null,"abstract":"","PeriodicalId":10275,"journal":{"name":"Clinical and Molecular Hepatology","volume":null,"pages":null},"PeriodicalIF":14.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141466590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma. 对水疱和血浆的多组学分析揭示了肝细胞癌的病因特异性特征。
IF 14 1区 医学
Clinical and Molecular Hepatology Pub Date : 2024-07-01 Epub Date: 2024-03-15 DOI: 10.3350/cmh.2024.0042
Jiwon Hong, Jung Woo Eun, Geum Ok Baek, Jae Youn Cheong, Seryoung Park, Soon Sun Kim, Hyo Jung Cho, Su Bin Lim
{"title":"Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma.","authors":"Jiwon Hong, Jung Woo Eun, Geum Ok Baek, Jae Youn Cheong, Seryoung Park, Soon Sun Kim, Hyo Jung Cho, Su Bin Lim","doi":"10.3350/cmh.2024.0042","DOIUrl":"10.3350/cmh.2024.0042","url":null,"abstract":"<p><strong>Background/aims: </strong>Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality worldwide. Despite identification of several biomarkers for HCC diagnosis, challenges such as low sensitivity and intratumoral heterogeneity have impeded early detection, highlighting the need for etiology-specific blood biomarkers.</p><p><strong>Methods: </strong>We generated whole-transcriptome sequencing (WTS) and targeted proteome data from buffy coat and plasma samples from HCC patients. By integrating etiological information on viral infection, we investigated the etiology-specific gene expression landscape at the blood level. Validation of differentially expressed genes (DEGs) was performed using publicly available RNA-seq datasets and qRT‒PCR with AUC analyses.</p><p><strong>Results: </strong>Differential expression analyses with multiomics data revealed distinct gene expression profiles between HBV-associated HCC and nonviral HCC, indicating the presence of etiology-specific blood biomarkers. The identified DEGs were validated across multiple independent datasets, underscoring their utility as biomarkers. Additionally, single-cell RNA-seq analysis of HCC confirmed differences in DEG expression across distinct immune cell types.</p><p><strong>Conclusion: </strong>Our buffy coat WTS data and plasma proteome data may serve as reliable sources for identifying etiology-specific blood biomarkers of HCC and might contribute to discovery of therapeutic targets for HCC across different etiologies.</p>","PeriodicalId":10275,"journal":{"name":"Clinical and Molecular Hepatology","volume":null,"pages":null},"PeriodicalIF":14.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11261225/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140130917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信